The search for an effective COVID-19 treatment showed signs of promise, with two major pharmaceutical companies this week announcing positive results for experimental drugs that converged with the rapid push toward a potential vaccine.
Regeneron (REGN) on Wednesday showed that its antibody cocktail therapy reduced the viral load in patients. The company reiterated the treatment has additional potential as a pseudo-vaccine that can be taken as protective treatment rather than just after an infection, and expects to publish the complete data in a medical journal in the near-term.
Regeneron’s data follows positive news from Eli Lilly (LLY) on an antibody treatment that reduced recovery time in hospitalized covid patients, and builds on existing efforts to try and mitigate the coronavirus’ spread. This week, global deaths surged over 1 million, with Europe and the U.S. battling against a dreaded second wave of infections.
In a research note,